Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 1,800 shares of the business’s stock in a transaction dated Monday, September 19th. The stock was purchased at an average cost of $10.18 per share, for a total transaction of $18,324.00. Following the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $31,241,921.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Tuesday, September 13th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was purchased at an average cost of $9.95 per share, for a total transaction of $99,500.00.
  • On Monday, September 12th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was purchased at an average cost of $9.79 per share, for a total transaction of $97,900.00.
  • On Friday, September 9th, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The stock was purchased at an average cost of $9.87 per share, for a total transaction of $35,532.00.
  • On Friday, September 2nd, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was purchased at an average cost of $9.28 per share, for a total transaction of $92,800.00.
  • On Thursday, August 25th, Phillip Md Et Al Frost acquired 48,400 shares of Opko Health stock. The stock was purchased at an average cost of $9.06 per share, for a total transaction of $438,504.00.
  • On Wednesday, August 24th, Phillip Md Et Al Frost acquired 15,000 shares of Opko Health stock. The stock was purchased at an average cost of $9.24 per share, for a total transaction of $138,600.00.
  • On Tuesday, August 23rd, Phillip Md Et Al Frost bought 29,000 shares of Opko Health stock. The shares were bought at an average cost of $9.53 per share, for a total transaction of $276,370.00.
  • On Monday, August 22nd, Phillip Md Et Al Frost bought 11,800 shares of Opko Health stock. The shares were bought at an average cost of $9.76 per share, for a total transaction of $115,168.00.
  • On Friday, August 19th, Phillip Md Et Al Frost bought 15,000 shares of Opko Health stock. The shares were bought at an average cost of $9.82 per share, for a total transaction of $147,300.00.
  • On Thursday, August 18th, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were bought at an average cost of $9.87 per share, for a total transaction of $98,700.00.

Shares of Opko Health Inc. (NYSE:OPK) opened at 10.50 on Wednesday. The firm has a market capitalization of $5.78 billion and a PE ratio of 43.93. Opko Health Inc. has a 52 week low of $7.12 and a 52 week high of $11.85. The firm’s 50-day moving average is $9.80 and its 200 day moving average is $10.08.

Opko Health (NYSE:OPK) last issued its earnings results on Monday, August 8th. The company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.05. The firm earned $357.10 million during the quarter, compared to analyst estimates of $324.11 million. The firm’s revenue was up 742.2% compared to the same quarter last year. During the same period last year, the business earned ($0.09) EPS. On average, equities analysts forecast that Opko Health Inc. will post ($0.05) earnings per share for the current year.

Several analysts have weighed in on OPK shares. Jefferies Group reissued a “hold” rating on shares of Opko Health in a research report on Wednesday, August 17th. JPMorgan Chase & Co. set a $14.00 target price on shares of Opko Health and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Deutsche Bank AG dropped their target price on shares of Opko Health from $11.00 to $10.00 and set a “hold” rating on the stock in a research report on Thursday, June 16th. Oppenheimer Holdings Inc. reissued an “outperform” rating on shares of Opko Health in a research report on Saturday, June 25th. Finally, Standpoint Research started coverage on shares of Opko Health in a research report on Friday, June 3rd. They set a “buy” rating and a $16.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $13.20.

A number of hedge funds have recently modified their holdings of OPK. Bridger Management LLC purchased a new stake in shares of Opko Health during the first quarter valued at $13,863,000. First Trust Advisors LP boosted its stake in shares of Opko Health by 164.8% in the second quarter. First Trust Advisors LP now owns 1,526,964 shares of the company’s stock valued at $14,262,000 after buying an additional 950,355 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Opko Health by 90.7% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,897,107 shares of the company’s stock valued at $17,687,000 after buying an additional 902,185 shares during the period. State Street Corp boosted its stake in shares of Opko Health by 11.6% in the second quarter. State Street Corp now owns 7,454,724 shares of the company’s stock valued at $69,627,000 after buying an additional 773,867 shares during the period. Finally, BlackRock Advisors LLC boosted its stake in shares of Opko Health by 305.8% in the second quarter. BlackRock Advisors LLC now owns 817,637 shares of the company’s stock valued at $7,637,000 after buying an additional 616,140 shares during the period.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.